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Risk stratiﬁcation is important to identify patients with acute myelogenous leukemia (AML) who might
beneﬁt from allogeneic hematopoietic stem cell transplantation (allo-HSCT) in ﬁrst complete remission. We
retrospectively studied 150 patients with AML and diagnostic cytogenetic abnormalities who underwent
myeloablative allo-HSCT while in ﬁrst complete remission to evaluate the prognostic impact of persistent
cytogenetic abnormalities at allo-HSCT. Three risk groups were identiﬁed. Patients with favorable/interme-
diate cytogenetics at diagnosis (n ¼ 49) and patients with unfavorable cytogenetics at diagnosis but without
a persistent abnormal clone at allo-HSCT (n ¼ 83) had a similar 3-year leukemia-free survival of 58%-60%
despite the higher 3-year relapse incidence (RI) in the latter group (32.3%, versus 16.8% in the former group).
A third group of patients with unfavorable cytogenetics at diagnosis and a persistent abnormal clone at allo-
HSCT (n ¼ 15) had the worst prognosis, with a 3-year RI of 57.5% and 3-year leukemia-free survival of only
29.2%. These data suggest that patients with AML and unfavorable cytogenetics at diagnosis and a persistent
abnormal clone at allo-HSCT are at high risk for relapse after allo-HSCT. These patients should be considered
for clinical trials designed to optimize conditioning regimens and/or to use preemptive strategies in the
posttransplantion setting aimed at decreasing RI.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION independent prognostic signiﬁcance in patients with AML is
The current recommendations for allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT) in patients with
acute myelogenous leukemia (AML) in ﬁrst complete remis-
sion (CR1) are limited to patients in whom the risk of relapse
signiﬁcantly exceeds the risk of mortality from allo-HSCT,
based on cytogenetic stratiﬁcation into good-risk, interme-
diate-risk, and poor-risk AML. These recommendations are
summarized in the National Comprehensive Cancer Network
guidelines [1]. Of course, practicemaycontinue to evolvewith
increasing knowledge of the pathobiology of AML and iden-
tiﬁcation of new molecular markers. In that context, identi-
fying new independent prognostic features in addition to
well-established classical risk factors for high risk of relapse
after allo-HSCT will help optimize the decision-making
process for patients with AML undergoing allo-HSCT in CR1.
Studies of more sensitive and objective methods that can
detect leukemia cells undetectable bymorphology (ie,minimal
residual disease [MRD]) have provided a rationale for the
incorporationofMRDtesting inriskassignmentstrategies [2,3].
The presence of MRD at the time of allo-HSCT has emerged as
a valuable prognostic indicator of relapse posttransplantation
in patients with chronic myelogenous leukemia [4,5] and
pediatric acute lymphoblastic leukemia [6,7]; however, itsedgments on page 219.
quests: Betul Oran, MD, Department of
ell Therapy, University of Texas M.D.
Holcombe Blvd., Unit 423, Houston,
rson.org (B. Oran).
2013 American Society for Blood and Marrow
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the prognostic impact of a persistent abnormal karyotype
before allo-HSCT in patients with AML in CR1.PATIENTS AND METHODS
Patient Population
This study included patients age >18 years with AML with cytogenetic
abnormalities at initial diagnosis who were in ﬁrst morphological complete
remission at allo-HSCT, had either a matched sibling donor (MSD) or
a matched unrelated donor (MUD), and underwent ﬁrst allo-HSCT with
a myeloablative conditioning regimen between January 1, 2001, and June 1,
2011 at the University of Texas M.D. Anderson Cancer Center. The study
group included patients with a previous diagnosis of myelodysplastic
syndrome or a myeloproliferative disorder who progressed to AML. Treat-
ment protocols and this retrospective analysis were approved by the
University of Texas M.D. Anderson Cancer Center’s Institutional Review
Board. All patients provided written informed consent for allo-HSCT.Conditioning Regimen and Graft-versus-Host Disease Prophylaxis
The patients received a busulfan and ﬂudarabine conditioning regimen
consisting of i.v. busulfan either at a dose calculated to target an average
daily systemic exposure dose, represented by an area under the
concentration-versus-time curve of 6000 mMol$min  10%, or 130 mg/m2,
along with ﬂudarabine 40 mg/m2 for 4 days [9]. Six of the 150 patients
received cloforabine [10], and 9 received plerifaxor in addition to busulfan
and ﬂudarabine. MUD graft recipients received either equine antithymocyte
globulin 20 mg/kg/day for 3 days or rabbit antithymocyte globulin 0.5 mg/
kg/day for 1 day, followed by 1.5 mg/kg the next day and 2.0 mg/kg the day
after that. In 145 patients (96.6%), graft-versus-host disease (GVHD)
prophylaxis consisted of tacrolimus and methotrexate 5 mg/m2 i.v. on
posttransplantation days 1, 3, 6, and 11. Fourteen of these 145 patients also
received pentostatin as described previously [11]. The other 5 patients
received posttransplantation cyclophosphamide for GVHD prophylaxis.Transplantation.
Table 1
Clinical and Transplantation Characteristics of the Study Population
NKAT
(n ¼ 132)
AKAT
(n ¼ 18)
n % n % P
Age, years
Median 49 50.5
IQR 36-55 39-56 .70
Sex
Female 63 47.7 6 33.3
Male 69 52.3 12 66.7 .20
Secondary AML
No 120 90.9 11 61.1
Yes 12 9.1 7 38.9 <.001
Cytogenetic risk group
Favorable/intermediate 49 37.1 3 16.7
Unfavorable 83 62.9 15 83.3 .09
CR with recovery of PBSC counts
Yes 122 92.4 11 61.1
No 10 7.6 7 38.9 <.001
Time from cytogenetic evaluation
to HSCT, days
Median 16 18
IQR 15-19 14-29 .30
Donor type
MRD 73 55.3 9 50.0
MUD 59 44.7 9 50.0 .70
Source of stem cells
BM 44 33.3 6 33.3
PBSC 88 66.7 12 66.7 1.0
Time from diagnosis to HSCT, months
Median 5.1 5.2
IQR 4-7.6 4-9.1 .30
NKAT indicates normal karyotype at transplantation; AKAT, abnormal
karyotype at transplantation; IQR, interquartile range; CR, complete
remission; PBSC, peripheral blood stem cells; HSCT, hematopoietic stem cell
transplantation; MRD, matched related donor; MUD, matched unrelated
donor; BM, bone marrow; PBSC, peripheral blood stem cells.
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All samples were analyzed by standard cytogenetic techniques. At least
20 metaphases from bone marrow (BM) were analyzed before a karyotype
was deﬁned as normal. For samples with abnormal cytogenetics, analyses
with fewer than 20 metaphases were acceptable. An abnormality was
considered clonal and thus mentioned in the karyotype when at least
2 metaphases had the same aberration in cases of a structural abnormality
or an extra chromosome, in accordance with the International System for
Human Cytogenetic Nomenclature [12]. Any monosomy had to be present in
at least 3 metaphases. Cytogenetic risk group was assigned based on criteria
published by the Southwest Oncology Group and Eastern Cooperative
Oncology Group [13]. The unfavorable-risk group included patients
with 5/del(5q), 7/del(7q), inv(3q), abn 11q, 20q, or 21q, del(9q), t(6;9),
t(9;22), abn 17p, or a complex karyotype (3 or more abnormalities). All other
patients and patients with inv(16)/t(16;16) with or without any additional
abnormalities and with t(8;21) without del(9q) and not part of a complex
karyotype and who retained their favorable characterization were included
in the intermediate/favorable-risk group.
Complete remission (CR) was deﬁned as 5% blast cells, no Auer rods,
and no cluster of blast cells on BM analysis, as well as no evidence of
extramedullary leukemia. Patients with an absolute neutrophil count
<1000/mL and a platelet count <100,000/mL with transfusion dependence
were classiﬁed as CR incomplete (CRi). Relapse was deﬁned as 5% blasts in
the BM or the development of extramedullary leukemia.
Statistical Analyses
The primary study endpoint was cumulative incidence of relapse (CIR).
Other study endpoints included probabilities of leukemia-free survival
(LFS), overall survival (OS), and transplantation-related mortality (TRM). LFS
was deﬁned as survival without disease progression or relapse; patients
alive without disease progression or relapse were censored at the time of
last follow-up. OS was deﬁned as the time from stem cell infusion to death
from any cause. Patients who were alive were censored at the time of last
contact.
Patient and transplant characteristics by persistence of an abnormal
clone at allo-HSCT were compared using the c2 test for categorical data and
the Wilcoxon rank sum test for continuous data. LFS and OS were calculated
using the Kaplan-Meier method. Univariate comparisons of all endpoints
were performed using the log-rank test. Cumulative incidence was used to
estimate the endpoints of CIR and TRM. A Cox proportional hazards model
[14] or the Fine and Gray method [15] for competing hazards was used for
multivariate regression. Variables included in the models were age
(50 years versus>50 years), sex, secondary AML, cytogenetic risk group at
diagnosis (favorable/intermediate versus unfavorable), CR with recovery of
peripheral blood stem cell (PBSC) counts, donor type (MSD versus MUD),
and presence of persistent abnormal clone at allo-HSCT. Because stem cell
source (BM versus PBSCs) was highly correlated with donor type, it not
included in the models. All factors were tested for the proportional hazards
assumption. The presence of a persistent abnormal clone detected by
cytogenetic analysis was included in each model. Analyses were performed
using Stata version 11.2 for Windows (StataCorp, College Station, TX).
RESULTS
Patient Characteristics
Among the 251 patients undergoing ﬁrst allo-HSCT with
myeloablative conditioning and had either an MSD or an
MUD in CR1, 156 (62.2%) had a cytogenetic abnormality at
diagnosis. Eighteen of these 156 patients (11.5%) had
a persistent clone with an abnormal karyotype at trans-
plantation (AKAT) that was identical to the clone present at
diagnosis, 132 (82.6%) had a normal karyotype at trans-
plantation (NKAT), and 6 (3.9%) did not undergo cytogenetic
evaluation before allo-HSCT. Patient and disease character-
istics are summarized in Tables 1 and 2. The interval between
cytogenetic evaluation and allo-HSCT did not differ between
patients with AKAT and those with NKAT (median, 18 days
[interquartile range (IQR), 14-29 days] versus 16 days [15-19
days]; P ¼ .30). Patients with AKAT were more likely to have
AML with unfavorable cytogenetics at diagnosis (P ¼ .09),
a higher frequency of secondary AML (P < .001), and
incomplete recovery of peripheral blood (PB) counts (CRi;
P < .001). Median age at transplantation, donor type (MSD
versus MUD), and stem cell source (BM versus PBSCs) were
similar in the 2 groups, as well as the median interval fromdiagnosis of AML to allo-HSCT (median, 5.2 months [range,
1.9-38.4 months] versus 5.2 months [3.3-77.4 months];
P ¼ .30).
The stem cell source was PBSCs in 100 patients (66.7%)
and BM in 50 patients (33.3%). PBSCs were used more often
in MSD transplantations than in MUD transplantations
(93.9% versus 33.8%; P < .001).
OS, LFS, CIR, and TRM
Themedian follow-upduration in allo-HSCTsurvivorswas
40.9 months (IQR, 16.6-63.4 months) and was similar in both
cytogenetic groups (P ¼ .80). Estimated 3-year OS was 52.4%
(95% conﬁdence interval [CI], 25.9%-73.4%) for patients with
AKAT and 66.7% (95% CI, 57.7%-74.4%; P ¼ .03) for patients
with NKAT, and estimated 3-year LFS was 36.5% (95% CI,
14.9%-58.6%) for the former and 59.0% (95% CI, 49.8%-67.1%)
for the latter. Although median OS was not reached (NR) in
both groups, median LFS was shorter in patients with AKAT
comparedwith thosewith NKAT (11.4months [IQR, 3months
to NR] versus 71.8 months [IQR, 8.4 months to NR]; P ¼ .06).
CIR was higher in patients with AKAT, with a 3-year
cumulative incidence of 46.9% (95% CI, 22.4%-68.1%),
compared with 26.5% in patients with NKAT (95% CI, 19.2%-
34.4%), although the difference did not reach statistical
signiﬁcance (P ¼ .10). The 3-year TRM rate was similar in the
2 groups (16.7% [95% CI, 4.1%-36.5%] in AKAT versus 14.4%
[95% CI, 8.9%-21.2%] in NKAT; P ¼ .90).
A longer interval between cytogenetic assessment and
allo-HSCT could theoretically allow time for reappearance of
disease, resulting in bias in classiﬁcation. Nonetheless,
a comparison of estimated OS, LFS, CIR, and TRM in 12 NKAT
Table 2
Clinical Characteristics of Patients with Abnormal Karyotype at Transplantation
Patient Age,
Years
Diagnostic Cytogenetic
Abnormality
Diagnostic Molecular
Abnormality
Therapy-
Related
AML
Antecedent
Hematologic
Disorder
CR Status
before
HSCT
Relapse
after
HSCT
Time to
Relapse
after HSCT
Therapy for
Relapse after HSCT
Survival after
Relapse
Survival
after HSCT
Cause of
Death
1 52 45, XY, add(5)(q11.2), t(6; 11)(q21; p15),
17, þmar
NPM-1(); C-KIT(); RAS();
FLT-3()
Yes No CRi No 2.3 months MOF
2 45 43-44, XY, del(5)(q13q33), 6, 7, 18,
add(19)(q13.1)
FLT-3(); RAS() No No CRi No 48.6 months Alive
3 43 47, XY, del(3)(q21q27), þ21 NP No MDS CR No 97.4 months Alive
4 32 44, XY, 5, del(7)(q22), þ11, 17, 20 NP No No CR Yes 19.6 months Palliative care 1 month 20.6 months Relapse
5 43 47, XX, der(3) inv(3)(p12q12) del(3)(q13.3),
t(11; 15)(q24; q21), þ21
NP No No CR No 97.4 months Alive
6 19 46, XY, t(3; 6)(q25; q26), del(5)(q13q33) NP No AA CRi Yes 4.9 months Fludarabine and
cytarabine; decitabine
5.8 months 10.8 monhts Leukemia
7 58 49, XY, þ8, þ9, þ14 FLT-3(); RAS() No No CRi No 34.7 months Alive
8 57 47, XY, del(7)(q22q36), þ9 NP No CMML CRi Yes 90 days Palliative care 1.3 months 4.3 months Leukemia
9 56 46, XY, del(7)(q11.2q32) FLT-3(þ); NMP1(); RAS() No No CR Yes 91 days 5-Azacitidine with
sorafenib; mitoxantrone
with etoposide
309 days 14 months Alive
10 52 46, XX, t(6; 9)(p23; q34) NPM-1(); C-KIT(); RAS();
FLT-3(þ)
Yes No CR No 12 months Alive
11 62 45, XY, 7 FLT-3(); RAS() No MDS CRi NE 1 month Graft failure
12 35 45, XY, t(3; 12)(q26.2; p13), 7 FLT3(þ); RAS(); C-KIT() No No CR Yes 341 days Idarubicin, cytarabine,
and decitabin
1120 days 48.7 months Alive
13 51 47-51, XX, 2, 3, 5, 7, 12, 13,
þ6-9 mar
NP No Ph negative
MPD
CRi Yes 62 days Palliative care 93 days 5.2 months Leukemia
14 46 46, XX, þi(1)(p10), del(4)(q21q35),
add(5)(q11.2), 17
NP No No CR Yes 134 days Decitabine
and SAHA
77 days 7 months Leukemia
15 40 46, XX, t(6; 11)(q27; q23) FLT3(þ); NPM1(); CEBPA() No No CRi No 13 months Alive
16 55 47, XY, þ8 FLT-3(); RAS() No MDS CR No 69 months Alive
17 30 46, XX, t(2; 3)(p23; q29) FLT-3(); RAS() No MDS CR No 36.1 months Alive
18 64 46, XY, del(12)(p12p13) FLT-3(þ); RAS() No CMML CRi NE 0.5 month MOF
AA indicates aplastic anemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; MOF, multiorgan failure; MPD, myeloproliferative disorder; NE, not evaluable; NP, not performed.
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Table 3
Univariate Analyses for Disease Outcomes
OS LFS RI TRM
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age
<50 years 1.0 1.0 1.0 1.0
50 years 1.7 1.1-2.9 .05 15 0.9-2.4 .10 0.9 0.5-1.6 .60 3.5 1.4-8.7 .008
Sex
Female 1.0 1.0 1.0 1.0
Male 2.0 1.1-3.5 .02 2.0 1.2-3.4 .05 1.5 0.8-2.7 .20 2.7 1.1-6.7 .03
Secondary AML
No 1.0 1.0 1.0 1.0
Yes 1.8 0.9-36 .10 1.3 0.6-2.6 .50 0.9 0.3-2.7 .90 1.5 0.5-4.5 .50
Cytogenetic risk group
Favorable/intermediate 1.0 1.0 1.0 1.0
Unfavorable 1.1 0.6-2.0 .60 1.4 0.8-2.4 .20 2.8 1.3-5.9 .009 0.5 0.2-1.1 .06
CR with recovery of PBSC counts
Yes 1.0 1.0 1.0 1.0
No 1.3 0.6-3.0 .40 1.4 0.7-2.7 .30 1.5 0.6-3.7 .40 0.7 0.2-3.3 .60
Cytogenetics at allo-HSCT
NKAT 1.0 1.0 1.0 1.0
AKAT 1.5 0.7-3.2 .30 1.8 0.9-3.5 .07 1.8 0.8-3.8 .10 1.1 0.3-4.0 .90
Donor type
MRD 1.0 1.0 1.0 1.0
MUD 0.8 0.5-1.4 .40 0.8 0.5-1.2 .20 0.6 0.3-1.0 .06 1.5 0.6-3.2 .30
Stem cell source
PBSC 1.0 1.0 1.0
BM 1.0 0.6-1.8 .90 1.0 0.6-1.7 .90 0.5 0.3-1.0 .06 2.9 1.3-6.5 .009
OS indicates overall survival; LFS, leukemia free survival; CIR, cumulative incidence of relapse; TRM, transplant relatedmortality; HR, hazard ratio; CI, conﬁdence
interval; CR, complete remission; PBSC, peripheral blood stem cell; allo-HCT, allogeneic hemetopoietic stem cell transplantation; NKAT, normal karyotype at
transplantation; AKAT, abnormal karyotype at transplantation; MRD, matched related donor; MUD, matched unrelated donor; BM, bone marrow.
Table 4
Summary of Outcomes: Three-Year Estimates of OS, LFS, RI, and TRM
Favorable/
Intermediate
Cytogenetics
Unfavorable
Cytogenetics
with NKAT
Unfavorable
Cytogenetics
with AKAT
95% CI 95% CI 95% CI P
OS 65.6 49.1-77.9 67.1 55.4-76.4 48.0 18.9-72.4 .50
LFS 60.8 45-73.5 57.8 46.2-67.8 29.2 8.4-54.2 .05
RI 16.8 7.9-28.7 32.3 22.2-42.6 57.5 27.5-78.9 .002
TRM 22.3 11.4-35.4 10.0 4.6-17.6 13.3 6.8-34.6 .20
OS indicates overall survival; LFS, leukemia free survival; CIR, cumulative
incidence of relapse; TRM, transplant related mortality; NKAT, normal
karyotype at transplantation; AKAT, abnormal karyotype at transplantation;
CI, conﬁdence interval.
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interval of28days showedno signiﬁcant differences (P¼ .50
for OS, P ¼ .30 for LFS, P ¼ .40 for CIR, and P ¼ .50 for TRM).
Univariate and multivariate regression models were
applied to analyze OS, LFS, CIR, and TRM. The unadjusted
hazard ratio (HR) of AKAT versus NKAT was 1.5 (95% CI,
0.7-3.2; P¼ .30) for OS,1.8 (95% CI, 0.9-3.5; P¼ .07) for LFS,1.8
(95% CI, 0.8-3.8; P ¼ .10) for CIR, and 1.1 (95% CI, 0.3-4.0;
P ¼ .90) for TRM (Table 3). Age 50 years and male sex were
associated with worse OS, with unadjusted HRs of 1.7 (95%
CI, 1.1-2.9; P ¼ .05) and 2.0 (95% CI, 1.1-3.5; P ¼ .02), respec-
tively. For LFS, male sex was prognostic of shorter LFS
(unadjusted HR, 2.0; 95% CI, 1.2-3.4; P ¼ .05). The risk of CIR
was increased by the presence of unfavorable cytogenetics at
the time of diagnosis (unadjusted HR, 2.8; 95% CI, 1.3-5.9;
P ¼ .009). Undergoing MUD allo-HSCT versus MSD and using
BM versus PBSCs as the stem cell source were associated
with decreased CIR, with unadjusted HRs of 0.6 (95% CI,
0.3-1.0; P¼ .06) and 0.5 (95% CI, 0.3-1.0; P¼ .06), respectively.
For TRM, age 50 years (unadjusted HR, 3.5; 95% CI, 1.4-8.7;
P ¼ .008), male sex (2.7; 95% CI, 1.1-6.7; P ¼ .03), and a BM
stem cell source (2.9; 95% CI, 1.3-6.7; P ¼ .009) were associ-
ated with worse outcomes.
After adjustment for other covariates, the adjusted HR of
AKAT versus NKAT was 1.5 (95% CI, 0.7-3.2, P ¼ .30) for OS
and 1.7 (95% CI, 0.9-3.2; P¼ .10) for LFS. For OS, age50 years
and male sex were prognostic factors (adjusted HR, 1.7; 95%
CI, 1.1-3.0; P ¼ .04 and 1.9; 95% CI, 1.1-3.3; P ¼ .03, respec-
tively). For LFS, only male sex was a poor prognostic factor
(adjusted HR, 2.0; 95% CI, 1.2-.3.3; P ¼ .007). In patients with
AKAT, the adjusted HR was 1.6 (95% CI, 0.8-3.4; P ¼ .20) for
CIR and 1.1 (95% CI, 0.3-4.0; P ¼ .90) for TRM. Unfavorable
cytogenetics at diagnosis was found to increase the CIR
(adjusted HR, 2.8; 95% CI, 1.3-5.9; P ¼ .009), whereas an MUD
allo-HSCT was associated with decreased CIR (adjusted HR,
0.5; 95% CI, 0.3-0.9; P ¼ .04). For TRM, age 50 years
(adjusted HR, 3.6; 95% CI, 1.5-8.8; P ¼ .005) and male sex(adjusted HR, 2.9; 95% CI, 1.1-7.3; P ¼ .03) were found to be
poor prognostic factors.
Regression Models after Combining Diagnostic
Cytogenetics and Presence of a Persistent Abnormal Clone
To test our hypothesis that AKAT is associated with
increased risk of relapse and subsequent decreased LFS, we
categorized the patients into 3 risk groups: favorable/inter-
mediate cytogenetics at diagnosis (n ¼ 49), unfavorable
cytogenetics at diagnosiswithNKAT (n¼83), andunfavorable
cytogenetics at diagnosis with AKAT (n¼ 15). Only 3 patients
with favorable/intermediate cytogenetics at diagnosis had
AKAT, and thus they were not included in this analysis.
We found that OS was similar among the 3 risk groups
(P ¼ .50), but LFS was lower in the patients with unfavorable
cytogenetics at diagnosis with AKAT compared with the
other 2 groups (P ¼ .05) (Table 4 and Figure 1A and B). CIR
was also highest in the patients with unfavorable cytoge-
netics at diagnosis with AKAT (unadjusted HR, 4.2; 95% CI,
1.6-11.0; P ¼ .003), followed by patients with unfavorable
cytogenetics at diagnosis with NKAT (unadjusted HR, 2.3;
95% CI, 1.1-5.0; P ¼ .03). The TRM rate was comparable in the
3 groups (P ¼ .20).
Figure 1. Probabilities of OS (A), LFS (B), CIR (C), and TRM (D) by diagnostic cytogenetics and persistence of an abnormal clone at allo-HSCT.
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combining diagnostic cytogenetics and persistence of an
abnormal clone at allo-HSCT revealed increased CIR (HR, 4.5;
95% CI, 1.7-11.9; P ¼ .003) and decreased LFS (adjusted HR,
2.4; 95% CI, 1.1-5.2; P ¼ .02) in the patients with unfavorable
cytogenetics with AKAT (Table 5). The patients with unfa-
vorable cytogenetics with NKAT also exhibited increased CIR
(adjusted HR, 2.4; 95% CI,1.1-5.3; P¼ .02). This risk groupwas
not prognostic for OS and TRM, however. Only male sex was
identiﬁed as a poor prognostic factor for OS (adjusted HR,1.9;Table 5
Multivariate Regression Models for OS, LFS, RI, and TRM
OS LFS
HR 95% CI P HR
Age
<50 years 1.0
50 years 1.7 0.9-2.9 .06
Sex
Female 1.0 1.0
Male 1.9 1.1-3.4 .03 2.0
Cytogenetic and persistent abnormal clone
Favorable/intermediate cytogenetics 1.0 1.0
Unfavorable cytogenetics with NKAT 1.1 0.6-2.1 .70 1.4
Unfavorable cytogenetics with AKAT 1.8 0.7-4.4 .20 2.4
Donor type
MRD
MUD
LFS indicates leukemia free survival; CIR, cumulative incidence relapse; TRM, tra
normal karyotype at transplantation; AKAT, abnormal karyotype at transplantatio95% CI, 1.1-3.4; P ¼ .03). Undergoing MUD allo-HSCT was
associated with decreased CIR (adjusted HR, 0.5; 95% CI,
0.3-0.9; P ¼ .04). For TRM, age 50 years was the sole poor
prognostic factor identiﬁed (adjusted HR, 3.4; 95% CI, 1.3-8.9;
P ¼ .01).
DISCUSSION
In this study involving a relatively large cohort (n ¼ 150)
of patients with AML in morphological CR1 treated with allo-
HSCT, residual disease, deﬁned as the persistence ofRI TRM
95% CI P HR 95% CI P HR 95% CI P
1.0
3.4 1.3-8.9 .01
1.0
1.2-3.4 .07 2.4 0.9-5.9 .06
1.0 1.0
0.8-2.4 .20 2.4 1.1-5.3 .02 0.5 0.2-1.2 .10
1.2-5.2 .02 4.5 1.7-11.9 .003 0.6 0.1-2.8 .50
1.0 1.0
0.5 0.3-0.9 .04 2.9 0.8-4.4 .1
nsplant related mortality; HR, hazard ratio; CI, conﬁdence interval; NKAT,
n; MRD, matched related donor; MUD, matched unrelated donor.
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time of transplantation (AKAT), was associated with poor
prognosis, with increased RI and decreased LFS. In our
cohort, AKAT was signiﬁcantly associated with other poor-
risk features, including secondary AML, unfavorable cytoge-
netics at diagnosis, and incomplete recovery of PB counts
before allo-HSCT, consistent with the literature [8]. However,
given that 15 of 18 patients in the AKAT group had unfavor-
able cytogenetics at diagnosis, this association was strongest
with unfavorable cytogenetics at diagnosis. Ultimately, we
combined diagnostic cytogenetic risk groups and the pres-
ence of cytogenetically abnormal clones at allo-HSCT to
identify 3 risk groups. The patients with favorable/interme-
diate cytogenetics at diagnosis and those with unfavorable
cytogenetics at diagnosis with NKAT exhibited a similar
3-year LFS of approximately 58%-60%. The third group of
patients with unfavorable cytogenetics at diagnosis and
AKAT had the worst prognosis, with a 3-year LFS of only
29.2%. OS differed among the groups, but the difference
between the group with unfavorable cytogenetics and NKAT
and the group with unfavorable cytogenetics and AKAT did
not reach statistical signiﬁcance, most likely owing to the
relatively small size of the latter group. Despite its limita-
tions, this risk classiﬁcation allowed us to control for the
confounding effect of diagnostic cytogenetics while inter-
preting the impact of a persistent abnormal clone at the time
of allo-HSCT on disease outcomes, and also provided
a prognostic tool for predicting CIR and LFS.
Persistent cytogenetic and/or molecular abnormalities
after induction chemotherapy are known to be poor inde-
pendent prognostic factors in AML [16,17]. For patients
without baseline cytogenetic or molecular abnormalities,
demonstration of MRD by multicolor ﬂow cytometry (MFC)
is also correlated with inferior outcomes [3]. Among the
techniques for detectingMRD, cytogenetic evaluation has the
disadvantages of decreased sensitivity (5%) and the need to
prepare metaphase chromosomes, with only 50%-55% of
patients with AML exhibiting recurrent cytogenetic abnor-
malities for AML at diagnosis. Despite the limitations of MRD
detection by chromosome banding, the persistence of cyto-
genetic abnormalities after induction or consolidation
therapy has been shown to be predictive of residual disease
in patients with AML [18-20]. Recently, Chen et al. [16] re-
ported the independent prognostic value of persistent
cytogenetic abnormalities at CR after induction chemo-
therapy in patients with AML, with only allo-HSCT improving
outcomes in this group of patients. Those ﬁndings support
the idea that the presence of MRD, even when detected by
a less-sensitive technique, can help predict outcomes and
guide the choice of treatment options.
The impact of MRD at allo-HSCT on disease outcomes and
its potential to deliver tailored therapies are not yet well
established. Walter et al. [8] reported a negative impact of
MRD at allo-HSCT on disease outcomes. In their study of 99
patients, the patients with MRD, indicated by positive MFC
results, had a 2-year disease-free survival (DFS) of 9%,
compared with 74.8% in those without MRD. Similar to our
ﬁndings, the authors reported an association of MRD with
other adverse risk factors, including unfavorable cytoge-
netics at diagnosis, suggesting that MRD may be a surrogate
marker for high-risk disease rather than an independent
poor prognostic factor for disease outcomes after allo-HSCT.
Whether MRD at allo-HSCT should be an indication for
further chemotherapy to eradicate the persistent clone, or
whether patients with MRD should undergo allo-HSCT withno further delay considering that the persistent clone is more
likely chemotherapy-resistant, has not yet been investigated.
The available data indicating no beneﬁt from postremission
chemotherapy before allo-HSCT in patients with AML in CR1
did not take the presence ofMRD into account [21-23]. On the
other hand, among patients with MRD at postinduction or
postconsolidation therapy, better outcomes have been re-
ported in those who proceed to allo-HSCT compared with
those who receive further chemotherapy. Maurillo et al. [3]
reported a 5-year relapse-free survival (RFS) of only 11% in
patients with MRD detected by MFC after consolidation who
did not undergo allo-HSCT, compared with 47% in those who
did undergo allo-HSCT. Buccisano et al. [24] reported
preliminary results of a risk stratiﬁcation model in AML CR1
aimed at identifying patients who might beneﬁt from allo-
HSCT earlier in their disease course. In their high-risk group,
including patients withMRD, they observed a 70% DFS rate in
the patients who underwent allo-HSCT, compared with 20%
in a historical control group who received further chemo-
therapy but did not proceed to allo-HSCT. Until a well-
designed randomized clinical trial investigating the role of
further chemotherapy to eradicate MRD before allo-HSCT is
available, it might be better to proceed with allo-HSCT with
no further delay considering the dismal outcomes in patients
with MRD who do not undergo transplantation.
In conclusion, our results indicate that MRD at allo-HSCT,
even when detected by a less-sensitive technique, can iden-
tify patients at high risk for relapse with decreased LFS after
transplantation. Despite the poor outcomes reported in this
population in the transplantation setting, these patients
should still be considered for allo-HSCT while in CR1, and
future efforts should focus on improving transplantation
outcomes in this high-risk group. Recent studies reporting
the use of hypomethylating agents given preemptively
in the posttransplantation setting [25] and modiﬁcations
of conditioning regimens [10,26] todecrease the riskof relapse
have shown promising results, and prospective multicenter
trials to conﬁrm those results in larger patient populations
should be prioritized within the transplantation community.
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